Project description
A European biobank to support immunotherapy research
Immunotherapy for cancer has not lived up to its initial promise, and results from clinical trials are variable. Therefore, the need arises to be able to predict response to immunotherapy or design combination therapies. For this purpose, the EU-funded IMMUcan project is building a state-of-the-art biobank of biological samples from cancer patients for whom immunotherapy has failed. Through a centralised workflow, the consortium will collect, process and store samples from various clinical trials in a uniform way. The samples will undergo immunoprofiling with cutting-edge technologies to investigate tumour–immune system interactions following or in the absence of treatment.
Objective
IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.
Fields of science
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
1200 Bruxelles / Brussel
Belgium
See on map
Participants (32)
1206 Geneve
See on map
1011 Lausanne
See on map
1445 Strassen
See on map
BRUSSELS Brussels / Bruxelles
See on map
3000 Leuven
See on map
WC2R 2LS London
See on map
Participation ended
75013 Paris
See on map
1070 Anderlecht
See on map
B15 2TT Birmingham
See on map
75231 Paris
See on map
69373 Lyon
See on map
8006 Zurich
See on map
1200 Bruxelles / Brussel
See on map
10117 Berlin
See on map
Participation ended
08003 Barcelona
See on map
75009 PARIS
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
7610001 Rehovot
See on map
75654 Paris
See on map
64293 Darmstadt
See on map
60064 North Chicago Il
See on map
51373 Leverkusen
See on map
RG21 4FA Basingstoke
See on map
TW89GS Brentford
See on map
2340 Beerse
See on map
94250 GENTILLY
See on map
92284 Courbevoie
See on map
92100 Boulogne Billancourt
See on map
75006 Paris
See on map
Participation ended
02139 Cambridge
See on map
00-927 WARSZAWA
See on map
08028 Barcelona
See on map
1066 EPALINGES
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.